Trial Profile
[(18)F]-FLT positron emission tomography (PET) predicting response to neoadjuvant therapy in rectal cancer patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 May 2016
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary)
- Indications Rectal cancer
- Focus Biomarker; Therapeutic Use
- 13 May 2016 New trial record